Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuqing Lou

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Frontiers in Immunology|June 2, 2023
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistanceYujing Li, Haohua Jiang, Fangfei Qian, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 27, 2010
A46G and C79G polymorphisms in the β2-adrenergic receptor gene (ADRB2) and essential hypertension risk: a meta-analysisYuqing Lou, Jinghua Liu, Yan Huang, et al.
Plos One|January 5, 2012
A-6G and A-20C polymorphisms in the angiotensinogen promoter and hypertension risk in Chinese: a meta-analysisWei Gu, Jielin Liu, Qiuli Niu, et al.
Thoracic Cancer|March 7, 2020
Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?Yuqing Lou, Runbo Zhong, Jianlin Xu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 16, 2013
NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysisYuqing Lou, Rong Li, Liwen Xiong, et al.
Frontiers in Oncology|December 6, 2021
The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes MellitusJie Qian, Weimin Wang, Lin Wang, et al.
Frontiers in Oncology|October 2, 2019
Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd LineJun Lu, Qin Shi, Lele Zhang, et al.
Oncotargets and Therapy|July 2, 2020
Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIsHai Zhang, Xiaohua Yang, Fang Hu, et al.
Frontiers in Immunology|October 4, 2021
<i>TP53</i> Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung CancerJun Lu, Runbo Zhong, Yuqing Lou, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in ChinaJianlin Xu, Bo Jin, Tianqing Chu, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Frontiers in Immunology|June 2, 2023
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistanceYujing Li, Haohua Jiang, Fangfei Qian, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 27, 2010
A46G and C79G polymorphisms in the β2-adrenergic receptor gene (ADRB2) and essential hypertension risk: a meta-analysisYuqing Lou, Jinghua Liu, Yan Huang, et al.
Plos One|January 5, 2012
A-6G and A-20C polymorphisms in the angiotensinogen promoter and hypertension risk in Chinese: a meta-analysisWei Gu, Jielin Liu, Qiuli Niu, et al.
Thoracic Cancer|March 7, 2020
Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?Yuqing Lou, Runbo Zhong, Jianlin Xu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 16, 2013
NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysisYuqing Lou, Rong Li, Liwen Xiong, et al.
Frontiers in Oncology|December 6, 2021
The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes MellitusJie Qian, Weimin Wang, Lin Wang, et al.
Frontiers in Oncology|October 2, 2019
Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd LineJun Lu, Qin Shi, Lele Zhang, et al.
Oncotargets and Therapy|July 2, 2020
Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIsHai Zhang, Xiaohua Yang, Fang Hu, et al.
Frontiers in Immunology|October 4, 2021
<i>TP53</i> Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung CancerJun Lu, Runbo Zhong, Yuqing Lou, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in ChinaJianlin Xu, Bo Jin, Tianqing Chu, et al.
Pageof 12